Iovance Biotherapeutics is now up 41% in a single month and the short book, while trimming at the margins for a third consecutive week, remains one of the heaviest in biotech — a standoff that continues to define the stock's character more than any other variable.
The positioning update this week shows incremental, not decisive, movement. Short interest has slipped further to 22.7% of the free float — roughly 90 million shares — down from 23.2% a week ago and well off the late-July peak above 121 million. The pace of covering remains slow relative to the stock's gains. Bears have returned around 33 million shares since mid-July, while the stock has added the better part of 80% in that same window. What makes this week's read slightly different is the direction of the borrow market: availability has continued to expand, now at 147%, up from 138% last week. That means the lending pool holds almost 1.5 shares available for every share currently borrowed — genuinely loose conditions for a stock carrying this level of short interest. Cost to borrow has also drifted lower, landing at 0.47%, down 7% on the week and down roughly 40% over the past month. Together, the picture is unchanged from recent weeks: a heavy short book under no mechanical pressure, with plenty of room for new shorts to add if they choose to.
Options positioning has edged more cautious. The put/call ratio is running at 0.35, its highest reading since early August and about 1.4 standard deviations above the 20-day mean of 0.31. It remains well below the 52-week high of 0.37, so this isn't a screaming defensive signal — but the drift is consistent. The PCR has climbed steadily from the 0.28-0.29 range that prevailed through late July, a quiet shift toward incrementally more hedged positioning as the stock runs into resistance near recent highs. The short score has meanwhile edged down to 70.9, from a peak of 74.7 immediately after earnings — still elevated in absolute terms, but trending lower as short interest slowly bleeds and the borrow market loosens.
The Street has responded to the post-earnings setup with broad target upgrades. Mizuho raised its target to $11 on August 18, maintaining Outperform. Barclays moved to $13 from $11 on August 7, also staying Overweight. Citizens lifted its target to $8 from $5 on the same day. All three maintained existing positive ratings — no new converts, but rising conviction on price levels. The consensus mean target is $9.33 against a current price of $7.03, implying roughly 33% further upside from here on the Street's base case. The bull argument centers on the growing TIL immunotherapy franchise and pipeline expansion; the bear case points to high manufacturing costs, ongoing losses, and execution risk on the commercial ramp. The EV/EBITDA multiple at -18.3 and a negative earnings yield reflect a company the market is valuing on optionality and commercial trajectory, not current profitability.
Institutional flows add some texture. BlackRock added 5.9 million shares in the most recent reported period to 8.2% of shares outstanding, while State Street added 7 million shares to reach 5.4%. Both moves were reported as of July 31, placing them before the August 6 earnings print that sent the stock up 46% in a day. Two Sigma's last reported position showed a 9.3 million share addition, though that data extends only to March 31. The net insider picture is modest — the CFO sold around 21,000 shares on August 6, paired with an award, while the CCO made a similarly small tax-related sale on August 10. Significance scores for both are minimal. The insider flow is not a signal either way.
The next scheduled earnings event is November 6. With that more than eleven weeks out, the near-term question for IOVA is whether the slow covering pace among shorts continues — or whether the loosening borrow conditions, now the easiest they have been since the pre-earnings period, attract fresh short supply into a stock that has now more than doubled off its lows.
See the live data behind this article on ORTEX.
Open IOVA on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
